Zimmer Biomet Holdings, Inc. Price & Performance (ZBH)

Zimmer Biomet has completed its acquisition of Paragon 28, making the company a wholly owned subsidiary. The $13-per-share cash deal, with potential for an additional $1 per share, strengthens Zimmer Biomet's presence in the fast-growing foot and ankle orthopedic market, aiming to accelerate growth and innovation in musculoskeletal care.123

Zimmer Biomet shares have dropped over 4% in the past week, driven by broader tariff concerns and increased trading volume. Despite the slump, analysts note the market may have overreacted, as the company’s exposure to tariffs is limited and recent product launches, such as the Persona Revision SoluTion Femur, remain positive.45

Zimmer Biomet currently trades with a P/E ratio above the sector average, and short interest has risen nearly 16% recently, signaling decreasing sentiment. However, its dividend payout ratio remains healthy at roughly 22%, and forecasts indicate sustainable or even improved dividend payments in the coming year.6